Please assess the completion status of the following clinical trial:

Trial Title: Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 ans,~* Performance status \< 2,~* Patient with metastatic breast cancer stade IV triple negative histologically confirmed~* Measurable or not disease but radiologically evaluable (RECIST 1.1),~* Negative Hormonal Receptors (Estrogens and/or Progesterone), HER-2 negative (Score 0 or 1 by Immunochemistry (IHC), negative FISH if score IHC 2),~* Patient with a progression during or after an anthracyclines and/or taxanes treatment receiving in neo-adjuvant or adjuvant regimen according to a resistance defined as a documented disease progression in the last 12 month after the last dose of taxanes or anthracyclines,~* Patient non previously treated by platinum salts,~* Hematological Functions: Neutrophiles ≥ 1,5.109/L, Platelets ≥ 100.109/L, Leucocytes \> 3 000/mm3, Hb \> 9g/dL,~* Hepatic Functions : total Bilirubin ≤ 1,5 time upper normal value (UNV), ASAT ≤ 2 ,5 time UNV, ALAT ≤ 2,5 time UNV, Alkaline Phosphatase ≤ 2,5 time UNV (\< 5 time UNV if case of hepatic metastasis),~* Renal Functions: Creatinine Clearance ≥ 60 mL/min,~* Patient signed the consent study form,~* Patient affiliated to a social security regimen (law of 9 August 2004).~Exclusion Criteria:~* Male Patients,~* Unknown hormonal Receptors~* Positive HER-2 (Score 3 in IHC or positive FISH)~* Pregnant or breastfeeding patient, or in age of pregnancy or predicting to be pregnant in the 6 months after the end of treatment,~* Patient not using contraceptive treatment during the treatment or after the 6 months after the end of treatment,~* Patient is a ward,~* Patient suffering from a non compatible disease with the enrollment in the study,~* Cardiac, renal, medullar, respiratory or hepatic insufficiency, clinically significant cardiovascular disease (including myocardiac infarct, unstable angina, symptomatic congestive heart failure, uncontrolled cardiac arrhythmia) \< 1 year before the study enrollment or randomisation,~* Patient with pulmonary lymphangitis or symptomatic pleural effusion (grade≥2), meningeal known carcinoma or symptoms of cerebromeningeal invasion, brain metastases unless treatment and stability for at least 4 weeks (no steroids or anti-convulsive).~* Uncontrolled diabetes,~* Psychiatric or neurological significant abnormality,~* Peripheric Neuropathy \> grade 2,~* Antecedent of hypersensibility to one of study treatment or one of used excipients,~* Urinary tract infection or acute hemorrhagic cystitis in progress~* Concomitant treatment with a medicine containing phenytoin or medication received in the context of a trial, or participation in another therapeutic clinical trial within \<30 days prior treatment with chemotherapy.~* Geographically unstable patient in the next 6 months or remaining distance to the treatment center making it difficult to follow in the study,~* Known history of abuse of narcotic or other drug or alcohol~* History of surgery within 28 days before the start of treatment,~* Patient unwilling or unable to comply with the requirements of the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cisplatin - Metronomic Cyclophosphamide (Type: EXPERIMENTAL): Cisplatin 25 mg/m² (day 1 to day 3) every 3 weeks Metronomic cyclophosphamide 150 mg (day 1 to day 14) every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues